Differential effects of four xylidine derivatives in the model of ischemia- and re-perfusion-induced arrhythmias in rats in vivo

European Journal of Pharmacology

Volumn 644, Issue 1-3, 2010, Pages 120-127

  Krzemiński, Tadeusz F ^a   Mitrega, Katarzyna ^a   Zorniak, Michał ^a   Porc, Maurycy ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

(Rat); Arrhythmia; Hemodynamics; Ischemia and re perfusion; Xylidine derivative

Indexed keywords

ARTICAINE; LIDOCAINE; MEPIVACAINE; ROPIVACAINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG MECHANISM; DRUG RESPONSE; DRUG STRUCTURE; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HEMODYNAMIC PARAMETERS; IN VIVO STUDY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION;

AMIDES; ANESTHETICS, LOCAL; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; BLOOD PRESSURE; CARTICAINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART RATE; LIDOCAINE; MALE; MEPIVACAINE; MYOCARDIAL REPERFUSION INJURY; RATS; RATS, SPRAGUE-DAWLEY; SEVERITY OF ILLNESS INDEX; TACHYCARDIA; TIME FACTORS; VENTRICULAR FIBRILLATION;

EID: 77955769028     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.06.036     Document Type: Article

References (54)

1. Alexander J.H., Granger C.B., Sadowski Z., Aylward P.E., White H.D., Thompson T.D., Califf R.M., Topol E.J. Prophylactic lidocaine use in acute myocardial infarction: incidence and outcomes from two international trials. The GUSTO-I and GUSTO-IIb investigators. Am. Heart J. 1999, 137:799-805.
2. Baller D., Bretschneider H.J., Hellige G. A critical look at currently used indirect indices of myocardial oxygen consumption. Basic Res. Cardiol. 1981, 76:163-170.
3. Bariskaner H., Tuncer S., Ulusoy H., Dogan N. Effects of ropivacaine and bupivacaine on hemodynamic parameters in rabbits. Methods Find. Exp. Clin. Pharmacol. 2001, 23:89-92.
4. Barrett T.D., Hayes E.S., Walker M.J.A. Lack of sensitivity for ventricular and ischaemic tissue limites the antiarrhythmic actions of lidocaine, quinidine and felcainide against ischaemia-induced arrhythmias. Eur. J. Pharmacol. 1995, 285:229-238.
5. Barrett T.D., Hayes E.S., Yong S.L., Zolotoy A.B., Abraham S., Walker M.J.A. Ischaemia selectivity confers efficacy for suppression of ischaemia-induced arrhythmias in rats. Eur. J. Pharmacol. 2000, 398:365-374.
6. Canvon S.J., Dobson G.P. Protection against ventricular arrhythmias and cardiac death using adenosine and lidocaine during regional ischemia in the in vivo rat. Am. J. Physiol. Heart Circ. Physiol. 2004, 287:1286-1295.
7. Canvon S.J., Dobson G.P. Pretreatment with an adenosine A1 receptor agonist and lidocaine: a possible alternative to myocardial ischemic preconditioning. J. Thor. Cardiovasc. Surg. 2005, 131:371-377.
8. Clark C., Foreman M.I., Kane K.A., McDonald F.M., Parratt J.R. Coronary artery ligation in anesthetized rats as a method for the production of experimental dysrhythmias and for the determination of infarct size. J. Pharmacol. Methods. 1980, 3:357-368.
9. Collinsworth K.A., Kalman S.M., Harrison D.C. The clinical pharmacology of lidocaine as an antiarrhythmic drug. Circulation 1974, 50:1217-1230.
10. Crome R., Hearse D.J., Manning A.S. Ischemia and reperfusion-induced arrhythmias: beneficial actions of nifedipine. J. Cardiovasc. Pharmacol. 1986, 8:1249-1256.
11. David J.S., Amour J., Duracher C., Ferretti C., Precloux P., Petit P., Riou B., Gueugniaud P.Y. Comparison of the effects of mepivacaine and lidocaine on rat myocardium. Eur. J. Anaesthesiol. 2007, 24:190-197.
12. DeSilva R.A., Hennekens C.H., Lown B., Casscells W. Lignocaine prophylactics in acute myocardial infarction: an evaluation of randomized trials. Lancet 1981, 8251:855-858.
13. Dobson G.P. Organ arrest, protection and preservation: natural hibernation to cardiac surgery: an invited review. Comp. Biochem. Physiol. (B). 2004, 139:469-485.
14. Dobson G.P., Jones M.W. Adenosine and Lignocaine: a new concept in non-depolarizing surgical arrest, protection and preservation. J. Thor. Cardiovasc. Surg. 2004, 127:794-805.
15. Dorian P., Cass D., Schwartz B., Cooper R., Barr A. Amiodaron as compared with lidocaine for shock-resistant ventricular fibrillation. New Eng. J. Med. 2002, 346:884-890.
16. El-Sherif N., Scherlag B.J., Lazzara R., Hope R.R. Re-entry ventricular arrhythmias in the late myocardial period. 4. Mechanism of action of lidocaine. Circulation 1977, 56:395-402.
17. Graff B.M. The cardiotoxicity of local anesthetics: the place of ropivacaine. Curr. Top. Med. Chem. 2001, 1:207-214.
18. Guinet P., Estebe J.P., Ratajczak-Enselme M., Bansard J.Y., Cheyanne F., Bec D., Leccore P., Wodey E., Ecoffey C. Electrocardiographic and hemodynamic effects of intravenous infusion of bupivacaine, ropivacaine, levobupivacaine, and lidocaine in anesthetized ewes. Reg. Anesth. Pain Med. 2009, 34:17-23.
19. Harrison D.C., Sprouse J.C., Morrow A.G. The antiarrhythmic properties of lidocaine and procainamide. Circulation 1963, 28:486-491.
20. Hine L.K., Laird N., Hewitt P., Chambers T.C. Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. Arch. Intern. Med. 1989, 149:2694-2698.
21. Janse M.J. A brief history of sudden cardiac death and its therapy. Pharmacol. Ther. 2003, 100:89-99.
22. Janse M.J., Opthof T., Kleber A.G. Animal models of cardiac arrhythmias. Cardiovasc. Res. 1998, 39:165-177.
23. Jewitt D.E., Kishon Y., Thomas M. Lignocaine in the management of arrhythmias after acute myocardial infarction. Lancet 1968, 1:266-270.
24. Koini E.N., Papazafiri P., Vassilopoulos A., Koufaki M., Horvath Z., Koncz I., Virag L., Papp G.J., Varro A., Calogeropoulou T. 5, 7, 8-Trimethyl-benzopyran and 5, 7, 8-trimethyl-1, 4,-benzoxazine aminoamide derivatives as novel antiarrhythmics against ischemia-reperfusion injury. J. Med. Chem. 2009, 52:2328-2340.
25. Krzeminski, T., 1991. Reperfusion-induced arrhythmias in anaesthetized rats; the essential model for the study potential antidysrhythmic and cytoprotective drugs according to the Lambeth Conventions. Cardiovascular and Respiratory in vivo studies (Eds.), Biomesstechnik-Verlag March GmbH, Germany. 125-130.
26. Li G.R., Ferrier G.R. Effects of lidocaine on reperfusion arrhythmias and electrophysiological properties in an isolated ventricular muscle model of ischemia and reperfusion. J. Pharmacol. Exp. Ther. 1991, 257:997-1004.
27. MacMahon S., Collins R., Peto R., Koster R.W., Yusuf S. Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. JAMA: J. Am. Med. Assoc. 1988, 260:1910-1916.
28. Matsumura N., Matsumura H., Abiko Y. Effects of lidocaine on the myocardial acidosis induced by coronary artery occlusion in dogs. J. Pharmacol. Exp. Ther. 1987, 242:1114-1119.
29. Moller R., Covino B.G. Cardiac electrophysiology properties of bupivacaine and lidocaine compared with those of ropivacaine, a new amide local anesthetic. Anesthesiol. 1997, 72:322-329.
30. Moscalenko A.V. Nonlinear nature of the antiarrhythmic effects of lidocain. Biofizika 2009, 54:62-67.
31. Nasser F.N., Walls J.T., Edwards W.D., Harrison C.E. Lidocaine-induced reduction in size of experimental myocardial infarction. Am. J. Cardiol. 1980, 46:967-975.
32. Niederdellmann H., Boretzky H., Frenel G., Ropp W., Wegner G. Untersuchungen zur Pharmakodynamik und Verträglichkeit des Lokalanasthetikums Carticain. Deutsch. Zahnarztliche Zeitschrift. 1976, 31:331-334.
33. Pitcanen M., Feldman H.S., Arthur G.R., Covino B.G. Chronotropic and inotropic effects of ropivacaine, bupivacaine, and lidocaine in the spontaneously beating and electrically paced isolated, perfused rabbit heart. Reg. Anesth. 1992, 17:183-192.
34. Polwin W., McDonald F.M., Brinkmann C., Hirche H., Addics K. Effects of lidocaine on catecholamine release in the ischemic rat heart. J. Cardiovasc. Pharmacol. 1987, 9:6-11.
35. Rahimtoola S.H., Sinno M.Z., Loeb H.S., Chuquimia R., Rosen K.M., Gunnar R.M. Lidocaine infusion in acute myocardial infarction. Arch. Int. Med. 1971, 128:416-418.
36. Robison S.L., Schroll M., Harrison D.C. The circulatory response of lidocaine in experimental myocardial infarction. Am. J. Med. Sci. 1969, 258:260-269.
37. Rosen K., Lau S., Weiss M., Damato A. The effect of lidocaine on atrioventricular and intraventricular conduction in man. Am. J. Cardiol. 1971, 25:1-5.
38. Ryan T.J., Anderson J.L., Antman E.M., Braniff B.A., Brooks N.H., Califf R.M., Hillis L.D., Hiratzka L.F., Rapaport E., Riegel B.J., Russell R.O., Smith E.E.J., Weaver W.D. ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J. Am. Coll. Cardiol. 1996, 28:1328-1428.
39. Sadowski Z.P., Alexander J.H., Skrabucha B., Dyduszynski A., Kuch J., Nartowicz E., Swiatecka G., Kong D.F., Granger C.B. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. Am. Heart J. 1999, 137:792-798.
40. Selye H., Bajusz E., Grasso S., Mendell P. Simple techniques for the surgical occlusion of coronary vessels in the rat. Angiology 1960, 11:398-407.
41. Southworth J.L., McKusick V.A., Peirce E.C., Rawson F.L. Ventricular fibrillation precipitated by cardiac catherization. J. Am. Med. Assoc. 1950, 143:717-720.
42. Stormant M.F., Lampe I., Barlow O.W. A comparison of the premedication values of several barbituric acid derivatives in relation to nitrous oxide anesthesia. J. Pharmacol. Exp. Ther. 1930, 39:165-175.
43. Tosaki A., Balint S., Szekeres L. Protective effect of lidocaine against ischemia and reperfusion-induced arrhythmias and shifts of myocardial sodium, potassium and calcium content. J. Cardiovasc. Pharmacol. 1988, 12:621-628.
44. Van Emous J.G., Nederhoff M.G.J., Ruigrok T.J.C., Van Echteld C.J.A. The role of Na+channel in the accumulation of intracellular Na+during myocardial ischemia: consequences for post-ischemic recovery. J. Mol. Cell. Cardiol. 1997, 29:85-96.
45. Vitola J.V., Forman M.B., Holsinger J.P., Atkinson J.B., Murray J.J. Reduction of myocardial infarct size in rabbits and inhibition of activation of rabbit and human neutrophils by lidocaine. Am. Heart J. 1997, 133:315-322.
46. Walker M.J.A., Curtis M.J., Hearse D.J., Cambell R.W.F., Janse M.J., Yellon D.M., Cobbe S.M., Coker S.J., Harness J., Harron D.W.G., Higgins A.J., Julian D.G., Lab M.J., Manning A.S., Northover B.J., Parratt J.R., Reimersma R.A., Riva E., Russell D.C., Sheridan D.J., Winslow E., Woodward B. The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia, infarction and reperfusion. Cardiovasc. Res. 1988, 22:447-455.
47. Weatherall J.A.C. Anesthesia in newborn animals. Brit. J. Pharmacol. 1960, 15:454-457.
48. Wells J.P., Beckett H. Articaine hydrochloride: a safe alternative to lignocaine. Dent. Update 2008, 35:253-256.
49. Wezler K., Bogler A. Die Dynamik des arteriellen Pulses. Der arterielle Blutdruck und seine Komponenten. Ergebn. Physiol. 1939, 41:292-306.
50. Wilson R.F., Wyche K., Christensen B.V., Zimmer S., Laxson D.D. Effects of adenosine on human coronary arterial circulation. Circulation 1990, 82:1595-1606.
51. Wyman M.G., Wyman R.M., Cannom D.S., Criley J.M. Prevention of primary ventricular fibrillation in acute myocardial infarction with prophylactic lidocaine. Am. J. Cardiol. 2004, 94:545-551.
52. Yellon D.M., Dana A. The preconditioning phenomenon: a tool for the scientist or clinical reality. Circ. Res. 2000, 87:543-550.
53. Yellon D.M., Downey J.M. Spotlight on preconditioning. Cardiovasc. Res. 2002, 55:425-428.
54. Zink W., Graf B.M. The toxicity of local anesthetics: the place of ropivacaine and levobupivacaine. Curr. Op. Anaesthesiol. 2008, 21:645-650.